AstraZeneca Pharma Ind Share Price

NSE: ASTRAZEN
|
Pharmaceuticals

₹ 5,948.50

-₹2.00 (-0.03%)
1D
Last updated 15 Oct, 2026, 11:42 IST

AstraZeneca Pharma Ind Share Price Today

As of 15 Oct 2026, AstraZeneca Pharma Ind share price is ₹5,948.50. The stock opened at ₹5,930.00, compared to its previous close of ₹5,950.50. During today's trading session, AstraZeneca Pharma Ind share price moved in the range of ₹5,872.50 to ₹5,969.00, with an average price of ₹5,920.75 for the day. Looking at its last 52-week, the stock has touched a low of ₹5,640.00 and a high of ₹9,849.50. On the performance front, AstraZeneca Pharma Ind share price has declined by 31.80% over the last six months and is down 34.76% on a year-on-year basis.

₹5,872.50
0.03% down today
₹5,969.00
1D LOW
1D HIGH

AstraZeneca Pharma Ind Returns Calculator

Volume
1,537
Average traded price
₹5,925.68
Last traded time
11:42:31 15 Oct
Last traded quantity
1
Circuit
L
H
₹4,760.50
₹7,140.50
52-week
L
H
₹5,640.00
₹9,849.50
Mkt Cap Cr
14,717.50
P/E
87.6
P/B
17.02
ROA
8.53%
ROE
21.49%
ROCE
25.53%
Quick Ratio
0.73
EV/EBITDA
57.15
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Astrazeneca Phar has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
Astrazeneca Phar appears overvalued compared to its peers
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,19,619.6935.035.0811.19%13.74%17.33%2.3121.42
Divis Laboratories2,46,222.1184.1814.6914.6%15.32%19.56%3.556.81
Torrent Pharmaceuticals1,76,300.5081.7720.964.87%25.49%13.85%0.7538.3
Zydus Lifesciences1,12,817.6824.574.168.57%18.59%17.35%0.9115.07
Laurus Labs1,10,823.44101.6420.9110.38%16.77%16.14%0.6854.71
Cipla1,07,446.7932.023.127.92%11.27%14.95%2.517.97
Dr. Reddy's Laboratories1,03,471.1432.52.725.48%11.07%12.54%1.3516.27
Mankind Pharma96,243.6447.326.07.36%11.74%13.13%0.7426.02
Aurobindo Pharma96,836.1026.12.566.34%9.25%11.76%1.1512.57
Lupin89,628.8316.153.9914.47%23.76%24.88%1.429.46

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

About AstraZeneca Pharma Ind

ISIN
INE203A01020
Sector Market Cap
₹ 14,717.50 Cr

AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).

AstraZeneca Pharma Ind Financial Highlights

  • Revenue: AstraZeneca Pharma Ind reported revenue of ₹2,304.07 crore in FY26 vs ₹1,756.92 crore in FY25. It showed an increase of 31.14% on a yearly basis.
  • Operating Profit: AstraZeneca Pharma Ind reported an operating profit of ₹252.20 crore in FY26 vs ₹156.36 crore in FY25. It showed an increase of 61.29% on a year-on-year basis.
  • Net Profit: AstraZeneca Pharma Ind reported a net profit of ₹187.52 crore in FY26 vs ₹115.74 crore in FY25. It showed an increase of 62.02% on a yearly basis.

AstraZeneca Pharma Ind Quarterly Result Highlights

  • AstraZeneca Pharma Ind reported revenue of ₹692.02 crore in Jun 2026, compared with ₹584.56 crore in Mar 2026, representing an increase of 18.38% on a quarter-on-quarter (QoQ) basis.
  • AstraZeneca Pharma Ind reported an operating profit of ₹50.75 crore in Jun 2026, compared with ₹58.14 crore in Mar 2026, representing a decrease of 12.71% on a quarter-on-quarter (QoQ) basis.
  • AstraZeneca Pharma Ind reported a profit of ₹37.93 crore in Jun 2026, compared with ₹44.88 crore in Mar 2026, reflecting a decrease of 15.49% on a QoQ basis.
  • The earnings per share (EPS) of AstraZeneca Pharma Ind stood at ₹75.01 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
75.00%
FII
2.68%
Other DII
0.07%
Retail and other
16.24%
Mutual funds
6.01%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20252.74%
Dec 20252.71%
Mar 20262.78%
Jun 20262.68%
1 day
+1.24%
1 week
+0.55%
1 month
-12.03%
1 year
-34.76%
3 years
+27.28%
5 years
+88.85%
Day
Open / Close
Change %
14 Oct 26
₹5,900.00 / ₹5,950.50
+1.24%
13 Oct 26
₹5,919.00 / ₹5,877.50
-0.70%
12 Oct 26
₹5,886.00 / ₹5,919.00
+1.40%
09 Oct 26
₹5,720.00 / ₹5,837.00
+2.05%
Show more

AstraZeneca Pharma Ind Financials

Full statement

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹2,275.58₹1,716.29₹1,295.53₹1,002.97
Other Income₹28.49₹40.63₹34.80₹26.10
Total Revenue₹2,304.07₹1,756.92₹1,330.33₹1,029.07
Total Expenses₹2,046.62₹1,503.77₹1,127.22₹854.74
Profit Before Tax₹252.20₹156.36₹219.54₹134.10
Tax₹64.68₹40.62₹58.03₹34.81
Profit After Tax₹187.52₹115.74₹161.51₹99.29
EPS - Basic₹75.01₹46.30₹64.60₹39.70
EPS - Diluted₹75.01₹46.30₹64.60₹39.70

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹252.20₹156.36₹219.54₹134.10
Income before WC changes₹285.55₹232.77₹212.47₹129.30
Change in Assets-₹503.30-₹385.82-₹95.73-₹80.09
Change in Liabilities₹285.92₹282.60-₹32.44₹49.90
Change in WC-₹217.38-₹103.22-₹128.17-₹30.19
Cash flow from Operations-₹15.14₹65.36₹27.87₹58.29
Cash flow from Investing₹18.69₹30.80₹21.74₹18.11
Cash flow from Financing-₹91.97-₹65.59-₹44.38-₹24.48
Total Cash Flow-₹88.42₹30.57₹5.23₹51.92
Cash (Start of the year)₹536.14₹505.57₹500.34₹448.42
Cash (End of the year)₹447.72₹536.14₹505.57₹500.34

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹249.17₹175.77₹145.32₹149.40
Current Assets₹1,739.93₹1,342.35₹932.71₹835.47
Total Assets₹1,989.10₹1,518.12₹1,078.03₹984.87
Current Liabilities₹981.81₹703.00₹357.12₹383.93
Net Current Asset₹758.12₹639.35₹575.59₹451.54
Non-Current Liabilities₹134.50₹44.77₹8.99₹12.25
Equity Capital₹872.79₹770.35₹711.92₹588.69
Total Equity & Liabilities₹1,989.10₹1,518.12₹1,078.03₹984.87
* All values are in INR Crore
Qty
Bid
2
5942
1
5941.5
1
5941
3
5940.5
2
5940
Ask
Qty
5948.5
6
5949
1
5949.5
1
5950.5
1
5951.5
1
Bid Total: 9
Ask Total: 10
Buy orders: 47%
Sell orders: 53%
Bearish
3
Neutral
5
Bullish
0
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
30.88
Neutral
ATR (14)
185.46
Neutral
STOCH(9,6)
58.36
Neutral
STOCH RSI (14)
100
Bearish
ADX(9)
73.76
Bearish
UO(9)
53.73
Neutral
ROC(12)
-8.52
Bearish
WillR(14)
-70.87
Neutral
Period
Simple value
Exponential vaue
5D
5860.7
5913.07
10D
5932.8
5993.38
20D
6257.48
6219.7
50D
6925
6786.33
100D
7624.94
7330.62
Volume trend — traded volume by day
15 Oct0L
14 Oct0L
13 Oct0L
12 Oct0L
9 Oct0L
8 Oct0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
AstraZeneca Pharma Ind
Pharmaceuticals
Add Stock
Add Another

AstraZeneca Pharma Ind Share Price FAQs

Disclaimer: The information on this page, including prices, charts, financials, ratios, and other data, is provided for informational and educational purposes only. It is not investment advice, a research report, or a recommendation or solicitation to buy, sell, or hold any security. Data is sourced from third parties and exchanges, may be delayed, and is not guaranteed to be accurate, complete, or timely. Upstox is not liable for any loss arising from its use.